Kano Model
for Manufacture of pharmaceuticals, medicinal chemical and botanical products (ISIC 2100)
The Kano Model has a very high industry fit for pharmaceuticals due to the high-stakes nature of R&D investments (IN05), the imperative for market differentiation, and the complex interplay of stakeholder needs (patients, HCPs, payers). Its 'primary' relevance and Priority 5 rating, coupled with...
Why This Strategy Applies
A theory of product development and customer satisfaction that classifies customer preferences into five categories.
GTIAS pillars this strategy draws on — and this industry's average score per pillar
These pillar scores reflect Manufacture of pharmaceuticals, medicinal chemical and botanical products's structural characteristics. Higher scores indicate greater complexity or risk — see the full scorecard for all 81 attributes.
Customer satisfaction by feature type
- Proven Safety Profile Buyers expect pharmaceutical products to be thoroughly tested and proven safe for human use; absence of safety causes outright rejection.
- Demonstrable Clinical Efficacy Products must reliably achieve their intended therapeutic effect, as lack of efficacy renders them useless and unacceptable.
- Full Regulatory Approval Without all necessary national and international regulatory clearances, products cannot be legally marketed or used, making this a fundamental requirement.
- Guaranteed Purity and Quality Buyers take for granted that pharmaceutical products meet stringent standards for purity, potency, and freedom from contaminants, which is essential for patient trust and health.
- Reliable Supply Chain Consistent and uninterrupted availability of essential medications is a non-negotiable expectation for healthcare providers and pharmacies to ensure patient access.
- Improved Tolerability (Fewer Side Effects) Products with fewer or milder side effects directly enhance patient adherence and satisfaction, leading to better outcomes and increased preference.
- Convenient Dosing Regimen Simpler administration schedules (e.g., once daily) improve patient compliance and ease of use for healthcare professionals, making the product more desirable.
- Demonstrable Cost-Effectiveness For payers and healthcare systems, products that offer a strong balance of efficacy and economic value (e.g., budget impact) are highly preferred and often influence formulary inclusion.
- Faster Onset of Action A quicker therapeutic effect provides more immediate relief or symptom control, directly improving patient experience and clinical utility.
- Broader Indication Coverage A single product effectively treating a wider range of patient conditions or subtypes within its approved indication offers greater clinical utility and efficiency for buyers.
- Integrated Digital Health Tools Unexpected digital solutions for disease management, adherence tracking, or patient education that extend beyond the medication itself can delight users and enhance overall value.
- Personalized Therapy Options Tailored treatments based on individual patient characteristics (e.g., genetic markers) offering highly specific efficacy and minimized adverse effects are often an unexpected but welcome innovation.
- Novel, Patient-Friendly Delivery Systems Innovative methods of administration (e.g., painless injections, transdermal patches for complex drugs, pleasant-tasting pediatric formulations) significantly improve patient experience beyond standard expectations.
- Proactive Patient Support Programs Comprehensive programs that anticipate and address patient needs (e.g., beyond-the-pill coaching, financial assistance navigation) go beyond standard product provision and create delight.
- Proprietary Chemical Synthesis Route Buyers are generally indifferent to the specific, internal chemical manufacturing process, as long as the final product consistently meets all quality and regulatory standards.
- Internal R&D Department Structure How the pharmaceutical company organizes its research and development teams internally is irrelevant to buyers, who only care about the outputs of R&D.
- Specific Manufacturing Site Location As long as the manufacturing facility is regulatory-approved, ensures quality, and guarantees supply, its geographic location is not a direct concern for buyers.
- Corporate Branding Design While brand recognition matters, the specific aesthetic design choices of a pharmaceutical company's overall corporate branding are largely indifferent to buyers focused on product efficacy and safety.
- Unnecessary Cold Chain Requirements Buyers dislike products that require specialized, costly, and logistically complex cold chain storage without a clear, superior medical justification, preferring more stable alternatives.
- Opaque Pricing and Rebate Systems Payers and providers actively dislike complex, non-transparent pricing structures that hinder clear assessment of true costs, budget impact, and value.
- Excessive Single-Use Plastic Packaging Environmentally conscious buyers and healthcare systems are increasingly disliking products that generate significant, unavoidable plastic waste.
- Mandatory Ancillary Services/Devices When a product forces the purchase of additional, potentially unneeded, or overly expensive services/devices, it can be viewed negatively by buyers seeking streamlined solutions.
- Ethically Problematic Sourcing Certain buyer segments actively dislike products manufactured using processes or sourcing raw materials that conflict with their ethical or religious values (e.g., animal testing, certain botanical origins).
Strategic Overview
The Kano Model is a powerful framework for prioritizing product features based on customer satisfaction, which is highly relevant for the pharmaceutical industry. It classifies features into 'basic' (must-haves, e.g., safety, efficacy), 'performance' (more is better, e.g., faster onset, improved tolerability), and 'delighters' (unexpected, innovative features, e.g., novel delivery systems, comprehensive patient support). In an industry characterized by exorbitant R&D costs (IN05) and lengthy development timelines, efficiently allocating resources to features that genuinely create stakeholder value is paramount.
This model enables pharmaceutical companies to differentiate products in crowded markets and optimize market access by identifying what truly drives satisfaction and value beyond core efficacy. It's crucial for making strategic R&D investment decisions, ensuring that resources are directed towards features that will maximize uptake, adherence, and commercial success, rather than merely meeting basic regulatory requirements. The model helps navigate market access challenges (CS01), balance innovation with affordability (MD03), and ensures R&D yields products that are not just effective but also highly desirable and commercially successful.
By systematically categorizing features from the perspective of patients, prescribers, and payers, the Kano Model mitigates the risk of 'Rapid Obsolescence and Competitive Pressure' (IN01) by ensuring product features are precisely aligned with unmet or under-satisfied needs. It also informs compelling value propositions for payers, demonstrating how specific product attributes translate into better outcomes and cost-effectiveness, thereby justifying pricing and securing reimbursement.
5 strategic insights for this industry
Safety, Efficacy, and Regulatory Approval are Non-Negotiable Basic Requirements
For any pharmaceutical product, proven safety, efficacy, and subsequent regulatory approval (e.g., FDA, EMA) are absolute 'basic' attributes. Without these foundational elements, no other feature, however innovative, will lead to market acceptance or commercial viability. These are the entry tickets to the market.
Performance Attributes Drive Competitive Preference and Adherence
Features such as improved tolerability (fewer side effects), convenient dosing regimens (e.g., once daily), faster onset of action, or reduced drug-drug interactions often fall into the 'performance' category. These attributes significantly influence physician prescribing preferences and patient adherence, creating a competitive advantage in a crowded market.
Beyond-the-Pill Solutions Act as Key 'Delighters'
True 'delighters' in pharma often extend beyond the molecule itself, encompassing comprehensive patient support programs, integrated digital health tools for disease management (e.g., remote monitoring, personalized apps), or novel, patient-friendly administration methods (e.g., smart auto-injectors). These innovations differentiate a drug, enhance the patient experience, and can justify premium pricing.
Payer Value Drivers Often Include Cost-Effectiveness and Real-World Outcomes
From a payer's perspective, cost-effectiveness, budget impact, and demonstrable real-world outcomes often function as 'performance' or even 'basic' requirements for reimbursement and formulary inclusion. 'Delighters' for payers might include risk-sharing agreements, data integration capabilities, or evidence of significant healthcare resource utilization reduction.
Feature Classification Evolves Over Product Lifecycle and Market Maturity
What begins as a 'delighter' (e.g., a breakthrough mechanism of action, a once-daily formulation) can quickly become a 'performance' attribute and eventually a 'basic' expectation as competitors introduce similar or superior features. Regular re-evaluation of Kano classifications is essential for maintaining competitive relevance and maximizing revenue post-patent expiry.
Prioritized actions for this industry
Conduct Multi-Stakeholder Kano Surveys for Pipeline and In-Market Products
Systematically survey patients, HCPs (physicians, nurses, pharmacists), and payers to classify existing and potential drug/service features. This identifies the most impactful areas for R&D investment, market differentiation, and value proposition development, addressing 'High R&D Investment for New Products' (MD01) and 'Market Access Barriers & Adoption Challenges' (CS01).
Prioritize R&D Portfolio Allocation Based on Kano-Derived Insights
Allocate R&D budget towards developing 'performance' and 'delighter' features that offer significant competitive advantage and address unmet needs, while ensuring 'basic' requirements are unequivocally met. This maximizes ROI on high R&D investments (IN05) and mitigates 'High R&D Investment Risk' (MD01) by focusing on value-generating attributes.
Develop 'Beyond-the-Pill' Delighter Strategies and Integrated Solutions
Invest in comprehensive patient support programs, digital therapeutics, integrated diagnostics, or novel drug delivery systems that enhance the patient experience and clinical outcomes. This creates strong brand loyalty, improves patient adherence, and supports premium pricing, addressing 'Balancing Innovation with Affordability' (MD03) and 'Market Access Barriers & Adoption Challenges' (CS01).
Regularly Re-evaluate Feature Categorization Throughout the Product Lifecycle
Re-assess Kano classifications for products nearing patent expiry, facing new competition, or as market expectations evolve. This adaptive approach ensures product strategies remain relevant and competitive, allowing for timely innovation or strategic divestment, addressing 'Maintaining Revenue Growth Post-Patent Expiry' (MD01) and 'Rapid Obsolescence and Competitive Pressure' (IN01).
Integrate Kano Insights into Value Dossier Development and Payer Communications
Frame drug features and their benefits in market access submissions and communications to payers according to their Kano classification. Clearly articulate how 'performance' and 'delighter' features translate into superior value, cost-effectiveness, or improved real-world outcomes to justify pricing and secure favorable reimbursement terms, addressing 'Increasing Payer Scrutiny and Price Pressure' (MD03) and 'Navigating Payer & Reimbursement Landscape' (IN04).
From quick wins to long-term transformation
- Conduct an internal workshop with product, R&D, and commercial teams to qualitatively categorize existing drug features (basic, performance, delighter) for a flagship product and a key pipeline asset.
- Run a small, focused Kano survey with a limited number of Key Opinion Leaders (KOLs) or patient advocacy group members to validate internal assumptions for a new pipeline asset.
- Identify one potential 'delighter' feature (e.g., improved patient education materials or a simple digital reminder tool) for a current product and pilot its introduction.
- Integrate quantitative Kano surveys into market research protocols for all late-stage pipeline products and key in-market assets, covering patients, HCPs, and payers.
- Establish a cross-functional 'Value Features' team (R&D, Marketing, Market Access, Medical Affairs) to align on feature prioritization and strategic development based on Kano insights.
- Develop a strategic roadmap for 'beyond-the-pill' services based on identified delighter opportunities, outlining technology requirements and regulatory pathways.
- Embed Kano methodology as a core component of the entire product lifecycle management process, from early discovery and development to post-market surveillance and strategic updates.
- Continuously monitor the competitive landscape and evolving stakeholder expectations to proactively shift feature focus and anticipate future 'basic' requirements or 'delighter' opportunities.
- Build internal capabilities for developing, integrating, and validating digital health solutions and personalized medicine approaches as core 'delighters' that differentiate products and improve patient outcomes.
- Applying Kano only to patients, neglecting the equally critical perspectives of HCPs, payers, and regulators.
- Misinterpreting stakeholder needs or assuming 'delighters' without rigorous qualitative and quantitative validation.
- Over-investing in 'delighters' before 'basic' and 'performance' needs are fully met and secured (e.g., robust efficacy and safety profile).
- Failing to adapt Kano classifications as the market matures, competitive offerings emerge, or patient/HCP expectations shift.
- Underestimating regulatory hurdles and compliance requirements for 'beyond-the-pill' services and digital health solutions (e.g., medical device regulations, data privacy).
Measuring strategic progress
| Metric | Description | Target Benchmark |
|---|---|---|
| New Product Feature Adoption Rate | Percentage of target HCPs prescribing or patients adopting newly introduced 'performance' or 'delighter' features (e.g., patient app downloads, use of specific device). | >60% within 1 year of launch for key features |
| Physician Preference Scores for Differentiated Features | HCP preference for the company's drug over competitors, specifically attributed to identified 'performance' or 'delighter' features in market research surveys. | Top 2 preference for X% of HCPs in targeted specialty |
| Patient Adherence & Satisfaction Scores (Linked to Features) | Measured via patient reported outcomes or direct surveys, specifically linking improved adherence and satisfaction to the presence or quality of 'performance' or 'delighter' features. | Improvement in adherence by X% and satisfaction scores by Y% for users of these features |
| Market Share Growth Attributable to Differentiated Features | Percentage increase in market share for a product, with growth specifically linked to the introduction or clear communication of identified 'performance' or 'delighter' features. | X% market share increase/maintenance in competitive markets |
| Reimbursement Success Rate & Formulary Positioning | Percentage of positive formulary decisions and preferred positioning for new drugs, directly correlated with the perceived value and utility of 'performance' and 'delighter' features by payers. | >70% positive formulary decisions with favorable access tiers |
Software to support this strategy
These tools are recommended across the strategic actions above. Each has been matched based on the attributes and challenges relevant to Manufacture of pharmaceuticals, medicinal chemical and botanical products.
Capsule CRM
10,000+ customers worldwide • Includes Transpond marketing platform
CRM contact and interaction tracking gives growing teams visibility into customer sentiment and service history — reducing the risk of complaints escalating through missed follow-ups or inconsistent handling
Cost-effective CRM for growing teams — manage contacts, track deals and pipeline, build customer relationships, and streamline day-to-day work. Paired with Transpond, a dedicated marketing platform for email campaigns and audience management.
Try Capsule FreeAffiliate link — we may earn a commission at no cost to you.
HubSpot
Free forever plan • 288,700+ customers in 135+ countries
CRM and NPS/CSAT tooling gives companies visibility into customer sentiment before it becomes a reputation event — and the infrastructure to respond with targeted, personalised messaging at scale
All-in-one CRM and go-to-market platform used by 288,700+ businesses across 135+ countries. Connects marketing, sales, service, content, and operations in one system — free forever plan to start, paid tiers to scale.
Try HubSpot FreeAffiliate link — we may earn a commission at no cost to you.
Other strategy analyses for Manufacture of pharmaceuticals, medicinal chemical and botanical products
Also see: Kano Model Framework